Atrial fibrillation associated with increased risk of venous thromboembolism

Chun-Cheng Wang; Cheng-Li Lin; Guei-Jane Wang; Chiz-Tzung Chang; Fung-Chang Sung; Chia-Hung Kao

doi:10.1160/TH14-05-0405

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2015; 113(01): 185-192
DOI: 10.1160/TH14-05-0405

Stroke, Systemic or Venous Thromboembolism

Schattauer GmbH

Atrial fibrillation associated with increased risk of venous thromboembolism

A population-based cohort study

Chun-Cheng Wang

¹Graduate of Clinical Medical Science, China Medical University, Taichung, Taiwan

²Division of Cardiology, Department of Internal Medicine, Taichung Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, Taichung, Taiwan

,

Cheng-Li Lin

³Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

⁶College of Medicine, China Medical University, Taichung, Taiwan

,

Guei-Jane Wang

¹Graduate of Clinical Medical Science, China Medical University, Taichung, Taiwan

⁴Department of Medical Research, China Medical University Hospital, Taichung, Taiwan

⁵Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan

,

Chiz-Tzung Chang

⁶College of Medicine, China Medical University, Taichung, Taiwan

⁷Division of Nephrology, China Medical University Hospital, Taichung, Taiwan

,

Fung-Chang Sung

⁸Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

,

Chia-Hung Kao

⁸Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

⁹Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan

› Author Affiliations

Abstract

Summary

Whether atrial fibrillation (AF) is associated with an increased risk of venous thromboembolism (VTE) remains controversial. From Longitudinal Health Insurance Database 2000 (LHID2000), we identified 11,458 patients newly diagnosed with AF. The comparison group comprised 45,637 patients without AF. Both cohorts were followed up to measure the incidence of deep-vein thrombosis (DVT) and pulmonary embolism (PE). Univariable and multivariable competing-risks regression model and Kaplan-Meier analyses with the use of Aelon-Johansen estimator were used to measure the differences of cumulative incidences of DVT and PE, respectively. The overall incidence rates (per 1,000 person-years) of DVT and PE between the AF group and non-AF groups were 2.69 vs 1.12 (crude hazard ratio [HR] = 1.92; 95 % confidence interval [CI] = 1.54-2.39), 1.55 vs 0.46 (crude HR = 2.68; 95 % CI = 1.97-3.64), respectively. The baseline demographics indicated that the members of the AF group demonstrated a significantly older age and higher proportions of comorbidities than non-AF group. After adjusting for age, sex, and comorbidities, the risks of DVT and PE remained significantly elevated in the AF group compared with the non-AF group (adjusted HR = 1.74; 95 %CI = 1.36-2.24, adjusted HR = 2.18; 95 %CI = 1.51-3.15, respectively). The Kaplan-Meier curve with the use of Aelon-Johansen estimator indicated that the cumulative incidences of DVT and PE were both more significantly elevated in the AF group than in the non-AF group after a long-term follow-up period (p<0.01). In conclusion, the presence of AF is associated with increased risk of VTE after a long-term follow-up period.

Keywords

Atrial fibrillation - venous thromboembolism - population-based cohort study - deep-vein thrombosis - pulmonary embolism

Full Text

References

References
1 Barra SN, Paiva LV, Providencia R. et al. Atrial fibrillation in acute pulmonary embolism: prognostic considerations. Emerg Med J 2014; 31: 308-312.
2 Carmichael AJ, Martin AM. Pulmonary embolism: a complication of right atrial thrombi due to atrial fibrillation. J R Soc Med 1991; 84: 313.
3 Torbicki A, Galié N, Covezzoli A et al. ICOPER Study Group. Right heart thrombi in pulmonary embolism. Results from the international cooperative pulmonary embolism registry. J Am Coll Cardiol 2003; 41: 2245-2251.
4 Szwast A, Hanna B, Shah M. Atrial fibrillation and pulmonary embolism. Pedi-atr Emerg Care 2007; 23: 826-828.
5 Flegel KM. When atrial fibrillation occurs with pulmonary embolism, is it the chicken or the egg?. CMAJ 1999; 160: 1181.
6 Gex G, Gerstel E, Righini M. et al. Is atrial fibrillation associated with pulmonary embolism?. J Thromb Haemost 2012; 10: 347-351.
7 Noel P, Gregoire F, Capon A. et al. Atrial fibrillation as a risk factor for deep vein thrombosis and pulmonary emboli in stroke patients. Stroke 1991; 22: 760-762.
8 Cheng TM. Taiwan’s National Health Insurance system: high value for the dollar. In Okma K. G. H., Crivelli L.. ed. Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. New Jersey: World Scientific; 2009. pp 71-204.
9 Cheng CL, Yang Kao YH, Lin SJ. et al. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepide-miol Drug Saf 2011; 20: 236-242.
10 Chang CH, Lin JW, Chiu FC. et al. Effect of radiofrequency catheter ablation for atrial fibrillation on morbidity and mortality: A nationwide cohort study and propensity score analysis. Circ Arrhythm Electrophysiol 2014; 07: 76-82.
11 Heit JA. Venous thromboembolism: disease burden, outcomes, and risk factors. J Thromb Haemost 2005; 03: 1611-1617.
12 Shorr AF, Kwong LM, Sarnes M. et al. Venous thromboembolism after orthopedic surgery: Implications of the choice for prophylaxis. Thromb Res 2007; 121: 17-24.
13 Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
14 Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
15 Prandoni P. Venous and arterial thrombosis: Two aspects of the same disease?. Clin Epidemiol 2009; 01: 1-6.
16 Gustafsson C, Blombäck M, Britton M. et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51.
17 Kahn SR, Solymoss S, Flegel KM. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ 1997; 157: 673-681.
18 Motoki H, Tomita T, Aizawa K. et al. Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period: comparison with chronic atrial fibrillation. Circ J 2009; 73: 1403-1407.
19 Sohara H, Amitani S, Kurose M. et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106-112.
20 Franchini M, Mannucci PM. Venous and arterial thrombosis: Different sides of the same coin?. Eur J Intern Med 2008; 19: 476-481.
21 Prandoni P. Venous thrombosis and atherosclerosis: is there a link?. J Thromb Haemost 2007; 05: 270-275.
22 Hansson PO, Eriksson H, Welin L. et al. Smoking and abdominal obesity. Risk factors for VTE among middle-aged men: “The study of men born in 1913” Arch Intern Med 1999; 159: 1886-1890.
23 Goldhaber SZ, Grodstein F, Stampfer MJ. et al. A prospective study of risk factors for pulmonary embolism in women. J Am Med Assoc 1997; 277: 642-645.
24 Deguchi H, Pecheniuk NM, Elias DJ. et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-899.
25 Hong C, Zhu F, Du D. et al. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005; 183: 169-174.
26 Ageno W, Prandoni P, Romualdi E. et al. The metabolic syndrome and the risk of venous thrombosis. A prospective, case control study. J Thromb Haemost 2006; 04: 1914-1918.
27 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
28 Collaborative overview of randomized trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. Br Med J 1994; 308: 235-246.
29 Eliasson A, Bergqvist D, Björck M. et al. Incidence and risk of venous throm-boembolism in patients with verified arterial thrombosis: a population study based on 23796 consecutive autopsies. J Thromb Haemost 2006; 04: 1897-1902.
30 Prandoni P, Pesavento R, Sørensen HT et al.. Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis. Findings from a cross-sectional survey. Eur J Intern Med 2009; 20: 470-473.
31 Lowres N, Neubeck L, Redfern J. et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110: 213-222.
32 Lowres N, Neubeck L, Salkeld G. et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014; 111: 1167-1176.
33 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position paper of the ESC working group on thrombosis - Task force on anticoagulants in heart disease. Thromb Haemost 2013; 110: 1087-1107.